MA50537A - Composés deutérés utilisés comme immunomodulateurs - Google Patents

Composés deutérés utilisés comme immunomodulateurs

Info

Publication number
MA50537A
MA50537A MA050537A MA50537A MA50537A MA 50537 A MA50537 A MA 50537A MA 050537 A MA050537 A MA 050537A MA 50537 A MA50537 A MA 50537A MA 50537 A MA50537 A MA 50537A
Authority
MA
Morocco
Prior art keywords
immunomodulators
compounds used
deuterated compounds
deuterated
compounds
Prior art date
Application number
MA050537A
Other languages
English (en)
Inventor
Pingchen Fan
Rebecca M Lui
Venkat Reddy Mali
Rajinder Singh
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA50537A publication Critical patent/MA50537A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050537A 2017-10-30 2018-10-29 Composés deutérés utilisés comme immunomodulateurs MA50537A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762578586P 2017-10-30 2017-10-30

Publications (1)

Publication Number Publication Date
MA50537A true MA50537A (fr) 2021-04-07

Family

ID=66333578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050537A MA50537A (fr) 2017-10-30 2018-10-29 Composés deutérés utilisés comme immunomodulateurs

Country Status (11)

Country Link
US (2) US20190144389A1 (fr)
EP (1) EP3703687A4 (fr)
JP (1) JP2021501175A (fr)
KR (1) KR20200109298A (fr)
CN (1) CN111741754A (fr)
AU (1) AU2018359214A1 (fr)
CA (1) CA3077395A1 (fr)
IL (1) IL273605A (fr)
MA (1) MA50537A (fr)
TW (1) TW201922704A (fr)
WO (1) WO2019089468A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3676262A4 (fr) 2017-09-03 2021-03-31 Angion Biomedica Corp. Hétérocycles vinyliques utilisés en tant qu'inhibiteurs de la kinase bispiralée associée à rho (rock)
US20190144389A1 (en) 2017-10-30 2019-05-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators
EP4233850A3 (fr) 2018-11-30 2023-09-20 ChemoCentryx, Inc. Formulations de capsules
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154993A0 (en) 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487796A4 (fr) 2002-03-28 2005-11-16 Neurogen Corp Biarylamides substitues en tant que modulateurs du recepteur c5a
JP2006508894A (ja) 2002-03-28 2006-03-16 ニューロジェン・コーポレーション Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン
JP2005530719A (ja) 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
WO2004018460A1 (fr) 2002-08-21 2004-03-04 Neurogen Corporation Aminomethyl imidazoles en tant que modulateurs de recepteurs c5a
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (fr) 2003-07-03 2005-01-27 Neurogen Corporation Derives (heterocycloalkyl)methyle substitues de type azole utilises comme modulateurs des recepteurs c5a
PL2381778T3 (pl) 2008-12-22 2017-01-31 Chemocentryx, Inc. Antagoniści c5ar
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
SG192254A1 (en) 2011-01-31 2013-08-30 Royal Medical Group Pllc Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
WO2016053890A1 (fr) * 2014-09-29 2016-04-07 Chemocentryx, Inc. Procédés et intermédiaires utilisés dans la préparation d'antagonistes de c5ar
NZ747259A (en) * 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists
US20190144389A1 (en) 2017-10-30 2019-05-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators

Also Published As

Publication number Publication date
WO2019089468A1 (fr) 2019-05-09
CA3077395A1 (fr) 2019-05-09
JP2021501175A (ja) 2021-01-14
EP3703687A4 (fr) 2021-04-07
US11807609B2 (en) 2023-11-07
IL273605A (en) 2020-05-31
KR20200109298A (ko) 2020-09-22
US20210276955A1 (en) 2021-09-09
US20190144389A1 (en) 2019-05-16
AU2018359214A1 (en) 2020-04-16
TW201922704A (zh) 2019-06-16
EP3703687A1 (fr) 2020-09-09
CN111741754A (zh) 2020-10-02

Similar Documents

Publication Publication Date Title
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52948A (fr) Composés
MA42293A (fr) Composés antibactériens
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA46373A (fr) Composés utilisés comme modulateurs de ror gamma
MA51669A (fr) Composés
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA53003A (fr) Composés
MA47420A (fr) Composés inhibiteurs d'oga
MA50537A (fr) Composés deutérés utilisés comme immunomodulateurs
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
MA50609A (fr) Énantiomères de thiazoles substitués utilisés comme composés antiviraux